Office of Commercialization and Economic Development
Office of Technology Commercialization

Methods for Preventing and Treating Graft Versus Host Disease

Technology #15-0064

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Jonathan Serody
Managed By
Kyle Bartholomew
Commercialization Manager 919.962.5921
Patent Protection
US Patent Pending US 2017/0360907

Infusion of ILC2 cells that are substantially free of ILC3 and MPP2 cells can be used to treat steroid refractory GvHd. Gastrointestinal tract graft-versus-host disease (GvHD) is relatively common following allogeneic stem cell transplantation however the prognosis is poor for steroid-refractory GvHD due to lack of alternate treatments. Ex vivo expansion and infusion of mouse ILC2 cells at key timepoints have diminished GvHD and provide encouraging results.
Advantages:
•  New treatment for steroid-refractory GvHD
•  Purified ILC2 cells are free of contaminating MPP2 and ILC3 cells 
•  Infusion can be from donor or recipient cells 

Related Publications: